BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BC Innovations | Nov 14, 2019
Emerging Company Profile

Cedilla: degrading proteins by modulating protein stability

While most protein degradation companies are developing bifunctional molecules that directly induce ubiquitin-mediated degradation, Cedilla is taking a different approach with monovalent small molecules that trigger a broader range of degradation mechanisms. “The concept of...
BC Extra | Oct 23, 2019
Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious. Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer...
BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases. With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen...
BC Extra | Jun 4, 2019
Company News

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes...
BC Week In Review | Sep 28, 2018
Financial News

Arvinas raises $120M in IPO

Arvinas Inc. (NASDAQ:ARVN) raised $120 million late Sept. 26 through the sale of 7.5 million shares at $16 in its bumped-up IPO. The price, at the top of its proposed $14-$16 range, values the company...
BC Extra | Sep 27, 2018
Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20...
BC Week In Review | Aug 31, 2018
Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
BC Extra | Aug 30, 2018
Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
Items per page:
1 - 10 of 10